- Miorin, Lisa;
- Kehrer, Thomas;
- Sanchez-Aparicio, Maria Teresa;
- Zhang, Ke;
- Cohen, Phillip;
- Patel, Roosheel S;
- Cupic, Anastasija;
- Makio, Tadashi;
- Mei, Menghan;
- Moreno, Elena;
- Danziger, Oded;
- White, Kris M;
- Rathnasinghe, Raveen;
- Uccellini, Melissa;
- Gao, Shengyan;
- Aydillo, Teresa;
- Mena, Ignacio;
- Yin, Xin;
- Martin-Sancho, Laura;
- Krogan, Nevan J;
- Chanda, Sumit K;
- Schotsaert, Michael;
- Wozniak, Richard W;
- Ren, Yi;
- Rosenberg, Brad R;
- Fontoura, Beatriz MA;
- García-Sastre, Adolfo
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic that is a serious global health problem. Evasion of IFN-mediated antiviral signaling is a common defense strategy that pathogenic viruses use to replicate and propagate in their host. In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs). Our results demonstrate that the viral accessory protein Orf6 exerts this anti-IFN activity. We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import. In addition, we show that a methionine-to-arginine substitution at residue 58 impairs Orf6 binding to the Nup98-Rae1 complex and abolishes its IFN antagonistic function. All together our data unravel a mechanism of viral antagonism in which a virus hijacks the Nup98-Rae1 complex to overcome the antiviral action of IFN.